Marksans Pharma Q1 FY27: consolidated PAT up 174 percent YoY
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.4 pts more than Nifty Microcap 250 and 11.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q1 FY27 unaudited results. Consolidated revenue rose about 36 percent YoY to Rs. 8,408 million; PAT jumped 174 percent to Rs. 1,594 million, aided by forex gains of Rs. 120 million and new acquisitions. Standalone PAT grew 44 percent to Rs. 690 million on Rs. 3,212 million revenue. Acquired QliniQ B.V. (Netherlands) for EUR 7.5 million and ABCnow GmbH (Germany) for EUR 1.1 million. 300,000 ESOPs granted under MESOS 2024. Auditors MSKA and Associates gave an unmodified opinion.
Strong YoY profit growth lifted by forex gains and acquisitions. Watch whether revenue and margin gains sustain in coming quarters.